Pfizer Celebrex Sales Reps Will Discuss Alternate Therapy, FDA Says

Pfizer will include FDA’s recommendation that prescribers consider alternative therapy in its promotion to doctors. The company has also agreed to suspend direct-to-consumer advertising for the COX-2 inhibitor following release of trial data showing an increased cardiovascular risk for patients on the drug.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet